发布求助
文献互助 智能选刊 最新文献

Cancer Therapy & Oncology International Journal最新文献

筛选
英文 中文
Low Total Pathologic Complete Response (tpCR) Rate to Preoperative Chemotherapy in Patients with Invasive Lobular Carcinoma of Breast (ILC): Analysis of Subgroup of Three Phase II Trials 浸润性乳腺小叶癌(ILC)患者术前化疗的总病理完全缓解率(tpCR)低:三个II期试验的亚组分析
Cancer Therapy & Oncology International Journal Pub Date : 2019-08-27 DOI: 10.19080/ctoij.2019.14.555899
P. K. Shahi
{"title":"Low Total Pathologic Complete Response (tpCR) Rate to Preoperative Chemotherapy in Patients with Invasive Lobular Carcinoma of Breast (ILC): Analysis of Subgroup of Three Phase II Trials","authors":"P. K. Shahi","doi":"10.19080/ctoij.2019.14.555899","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555899","url":null,"abstract":"Background: Total pathologic complete response (tpCR; ypT0/is ypN0) after preoperative chemotherapy (PCT) is associated with better outcome in locally advanced breast cancers. However, the tpCR rate according to histology is not usually considered in trials. Patients and Methods: Patients with invasive lobular breast carcinoma (ILC), including in 3 phase II trials (AT, ATX and TXH), were eligible. Expression of markers and clinical phenotypes (CPh) were determined by immunohistochemistry. The primary end-point was tpCR rate in patients with ILC. Secondary end-points were breast conservation surgery rate (BCSR), event-free survival (EFS), and overall survival (OS). Results: In the subgroup of patients with ILC (n=16), median age was 50 years, 56.25% was premenopausal, median tumor size was 5 cm, and 68.75% had clinically node involvement. Six patients (37.5%) had clinical stage II and 10 (62.5%) had clinical stage III. Hormone receptor positive disease was present in 93.75% of the patients, and median Ki-67 was 25%. CPh were Luminal A-like in 37.5%, Luminal B-like in 50%, HER2-positive in 6.25% and triple negative in 6.25% of tumors. Only 1 patient (6.25%) had a tpCR, and another patient had a pCR only in the breast. With a median follow-up of 146 months, median EFS was 120 months (95% CI: 68-139), and median OS was not reached. Ten-year EFS and OS probability was 47% and 60%, respectively. BCSR","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89125986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Perspectives of Epstein–Barr Virus-Associated Gastric Cancer Epstein-Barr病毒相关胃癌的新进展
Cancer Therapy & Oncology International Journal Pub Date : 2019-08-27 DOI: 10.19080/ctoij.2019.14.555900
B. B. Gárate
{"title":"New Perspectives of Epstein–Barr Virus-Associated Gastric Cancer","authors":"B. B. Gárate","doi":"10.19080/ctoij.2019.14.555900","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555900","url":null,"abstract":"","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87302393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fighting Cancer Stem Cells Via Armored Mesenchymal Stem Cells with Napabucasin: A New Strategy for Cancer Therapy 通过装甲间充质干细胞与Napabucasin对抗癌症干细胞:癌症治疗的新策略
Cancer Therapy & Oncology International Journal Pub Date : 2019-08-21 DOI: 10.19080/ctoij.2019.14.555897
M. Farahani
{"title":"Fighting Cancer Stem Cells Via Armored Mesenchymal Stem Cells with Napabucasin: A New Strategy for Cancer Therapy","authors":"M. Farahani","doi":"10.19080/ctoij.2019.14.555897","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555897","url":null,"abstract":"Cancer relapse and metastasis are associated with part of cancer cells with stem cell properties. These cancer stem cells are resistant to current treatment of cancer, such as chemotherapy and radiation therapy. Stem cell biologists hypothesized that inhibition of cancer stemness can effectively suppress metastasis and relapse. BBI608 (Napabucasin) is a small molecule which inhibits Stat3 cell signaling pathway and cancer stemness properties. This drug can block spherogenesis of cancer stem cell and kill them effectively. Recently rattle-type nanoparticles that are hollow nanospheres with mesoporous shells and metal cores are introduced for drug delivery. These types of the nanoparticle can effectively entrap small molecules and efficiently anchored to the surface of mesenchymal stem cells by specific antigen-antibody recognitions. Mesenchymal stem cells can track tumors and their micrometastasis after intravenous injection in the cancer animal models. We suggest that mesenchymal stem cells armored with entrapped Napabucasin in silica nanorattle can effectively track tumors and deliver Napabucasin to cancer stem cells to inhibit them and subsequently eradicate the tumor bulk. This protocol combined with current chemotherapeutic drugs can be employed for the treatment of cancer in particular metastatic cancer.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85091728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tracking Tumours into Number Community? – Yes, How and Why 追踪肿瘤进入数字社区?-是的，怎么做和为什么
Cancer Therapy & Oncology International Journal Pub Date : 2019-08-12 DOI: 10.19080/ctoij.2019.14.555896
Yimesgen Tarekegn Abeka
{"title":"Tracking Tumours into Number Community? – Yes, How and Why","authors":"Yimesgen Tarekegn Abeka","doi":"10.19080/ctoij.2019.14.555896","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555896","url":null,"abstract":"Statement of the Problem: Tumours are growths (of quantity) in humans with medical science literature. Isodigitals produced by pre-emptive multiplication are also growths (of quantity) in numbers with slight numeration science literature for now. The developer of inchoate numeration science literature somehow acquainted with the literature of tumours, upon encountering isodigitals would be prompted to surmise isodigitals as phenotypes (lookalikes) of tumours and be urged to explore their literatures for prospects of relationship between the two. Methodology and theoretical Orientation: Tumours and isodigitals are subjected to pentadic characterization with the five parameters of identity, structure, function, operation and application for methodology. The theoretical orientation of the method is that tumours and isodigitals as growths of quantity are classic examples of quantity which is defined as the phenomenal medium of manifestation of all things, whether material or non-material. So, the two can be compared and contrasted at will in the interest of science. Findings: Numeration science literature on isodigitals can borrow mode of classification of tumours from medical science literature on tumours, while medical science literature on tumours can borrow verbal formulary for the description of pattern of growth of tumours from numeration science literature on isodigitals. Conclusion and Significance: Tumours in humans and isodigitals in numbers are seen as phenotypes subsisting on manifestation of quantity. The peculiarities of one can serve as clues to the probing of the other for more light. Recommendations: The ideal of insight on quantity should be brought to bear on scientific engagements.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78660710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review on Canine Transmissible Venereal Tumor (CTVT) 犬传染性性病肿瘤研究进展
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-30 DOI: 10.19080/ctoij.2019.14.555895
Yimesgen Tarekegn Abeka
{"title":"Review on Canine Transmissible Venereal Tumor (CTVT)","authors":"Yimesgen Tarekegn Abeka","doi":"10.19080/ctoij.2019.14.555895","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555895","url":null,"abstract":"Tumor is a genetic disease. Damage to the cellular genome is a common feature for virtually all neoplasms, despite the facts that neoplasms arise in a broad variety of tissues and that diverse agents such as viruses, mutagenic chemicals, and radiation induce their outgrowth. The genetic damage produced by carcinogens is believed to be random, and many mutations may be inconsequential [1]. Canine transmissible venereal tumor (CTVT) also known as Sticker’s sarcoma, Sticker tumor, transmissible venereal tumor (TVT), contagious venereal tumor, transmissible lymphosarcoma, transmissible venereal sarcoma, veneral granuloma, infectious granuloma, canine condyloma, infectious sarcoma and contagious lymphosarcoma [2].","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87851910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
A Truncated Form of the Polarity Protein SCRIB Induces Apoptosis in MDA-MB231 Cells by Regulating Components of Several Signalling Pathways 极性蛋白SCRIB的截断形式通过调节几种信号通路成分诱导MDA-MB231细胞凋亡
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-26 DOI: 10.19080/ctoij.2019.14.555894
Joseph Papamathekis
{"title":"A Truncated Form of the Polarity Protein SCRIB Induces Apoptosis in MDA-MB231 Cells by Regulating Components of Several Signalling Pathways","authors":"Joseph Papamathekis","doi":"10.19080/ctoij.2019.14.555894","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555894","url":null,"abstract":"Polarity proteins are fundamental to the establishment and maintenance of breast tissue integrity, whereas alterations of their amino acid sequence and protein structure can drive breast cancer formation and progression. Scrib is a multi-functional scaffold protein whose proper localization within the cell is pivotal for its correct function. We report here that the ectopic expression of a truncated form of the polarity protein of the LRR domain, drives MDA-MB231 breast cancer cells to caspase 3-mediated apoptotic cell death. Furthermore, we identify the truncated Scrib as a regulator of JNK/c-Jun, Notch and Wnt/β-catenin signalling pathways. Our results indicate that the ectopic expression of the truncated Scrib in a breast cancer cell line with a specific background of genetic mutations (KRAS, AFRGAP1, BRAF, MYCL) activates a program of intracellular molecular alterations and promotes apoptosis.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83366701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cobalt-60 Source Loading: Necessity of A Rigid Protocol 钴-60源加载:严格协议的必要性
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-25 DOI: 10.19080/ctoij.2019.14.555893
G. George
{"title":"Cobalt-60 Source Loading: Necessity of A Rigid Protocol","authors":"G. George","doi":"10.19080/ctoij.2019.14.555893","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555893","url":null,"abstract":"Aim: To look if calculating the gantry angle position helps in source loading. Materials and Methods: The study was conducted in Advanced Cancer Diagnostic, Treatment and research Centre- Bathinda, India at the time of source loading in the Bhabhatron – II TAW teletherapy unit. There is no rigid protocol for calculating the angle in which source loading needs to be done. The study looks at various gantry angle positions in which source loading was attempted and failed and describes how to calculate the position in which source loading needs to be done; based on which successful loading was done. Result: Calculating the gantry angle position helps reduce source loading errors. Conclusion: By following a rigid protocol, the number of trials undertaken for the cobalt-60 source loading could be reduced, thus limiting the radiation exposure to all involved.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76876355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Cell Carcinoma with Duodenal Metastasis: A Rare Presentation 肾细胞癌合并十二指肠转移:一罕见的表现
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-23 DOI: 10.19080/ctoij.2019.14.555892
S. Goel
{"title":"Renal Cell Carcinoma with Duodenal Metastasis: A Rare Presentation","authors":"S. Goel","doi":"10.19080/ctoij.2019.14.555892","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555892","url":null,"abstract":"Renal cell carcinoma (RCC) is a notorious malignancy with variable metastatic sites and clinical patterns. Even the bowel is not spared and around 7% cases metastasize to small intestine [1]. The involvement of duodenum is a rare phenomenon and only nineteen cases have been reported in literature till date [2,3]. It is fairly expected that duodenal metastasis occurs in presence of widespread visceral and nodal metastases along with disease elsewhere in the body [2]. Solitary duodenal metastasis is presumed to be rare [4]. However, if we look at all the 19 reported cases, 12 had solitary duodenal lesion and seven patients was involved of other organs as well [2,3]. We hereby report a case that had duodenal metastasis one year after being diagnosed and treated for renal cell carcinoma.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77309514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Lung Cancer 肺癌的治疗
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-22 DOI: 10.19080/ctoij.2019.14.555891
R. Iqbal
{"title":"Treatment of Lung Cancer","authors":"R. Iqbal","doi":"10.19080/ctoij.2019.14.555891","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555891","url":null,"abstract":"","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86148238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy and Chemotherapy in Low-Grade Glioma (LGG) 低级别胶质瘤(LGG)的放疗和化疗
Cancer Therapy & Oncology International Journal Pub Date : 2019-07-17 DOI: 10.19080/ctoij.2019.14.555889
B. Saberi
{"title":"Radiotherapy and Chemotherapy in Low-Grade Glioma (LGG)","authors":"B. Saberi","doi":"10.19080/ctoij.2019.14.555889","DOIUrl":"https://doi.org/10.19080/ctoij.2019.14.555889","url":null,"abstract":"Although optimal timing is unclear, but radiotherapy is an important component of therapy for LGG. Early and delayed radiotherapy can be used for LGG depending on some factors like tumor associated symptoms and presence of risk factors determining the outcome. Poor prognostic factors can be incomplete resection, MIB-1 index elevation, astrocytic histology, more than 40 year of age, absence of 1p/19q-codeletion, large sizes and mutation in isocitrate dehydrogenase. In some studies, with using 50-54 Gy RT dose with 1.8 Gy per fraction, the overall survival rates were similar between the patients whom received radiotherapy in early phase or during progression phase of the disease [1-5].","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78542051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信